{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Comparison between arms at Day 28 of treatment","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.954","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 1 vs. Day 28 of treatment for the Placebo-First arm","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 1 vs. Day 28 of treatment for the Armodafinil arm","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.369","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Comparison between Day 28 and Day 56 of treatment for the Armodafinil arm","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.973","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"77.8","value":"161.3"},{"groupId":"OG001","spread":"163.2","value":"220.5"}]}],"title":"Day 1(n=18, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"81.2","value":"158.4"},{"groupId":"OG001","spread":"94.2","value":"159.8"}]}],"title":"Day 28 (n=19, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"78.7","value":"153.8"},{"comment":"Day 56 data was only evaluated for the Armodafinil arm","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Day 56 (n=15)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Cognitive test that gives a measure of various aspects of cognitive performance. Used to measure cognitive fatigue. The test consists of 25 circles containing 13 sequential numbers (1-13) and 12 sequential letters (A-L) positioned.\n\nThe test evaluates the time to correctly order letters and numbers; low times = better performance.","dispersionType":"Standard Deviation","groups":[{"description":"The patients receive armodafinil for all 56 days of the study.\n\nArmodafinil taken orally at 150 mg daily.","id":"OG000","title":"Armodafinil"},{"description":"These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).\n\nPlacebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.","id":"OG001","title":"Placebo-First"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Day 1, Day 28 and Day 56","title":"Trail Making Test B Score (TMT-B)","type":"PRIMARY","unitOfMeasure":"seconds"}